AVR RD 01
Alternative Names: AVR-02; AVR-RD-01Latest Information Update: 25 Jun 2024
At a glance
- Originator AVROBIO
- Developer Tectonic Therapeutic
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Alpha-galactosidase replacements; Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Fabry's disease
Most Recent Events
- 20 Jun 2024 AVROBIO has been merged with Tectonic Therapeutic to form Tectonic Therapeutic
- 04 Jan 2024 AVROBIO terminates licensing agreement with University Health Network for AVR RD 01 in Fabry's disease
- 31 Jan 2022 Discontinued - Phase-I for Fabry's disease (Treatment-experienced) in Canada (IV) (Form 10-K, December 2021, AVROBIO)